New surgical approaches for clinically high-risk or metastatic prostate cancer

References

• GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012; cited 2017 May. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
   Google Scholar
• Wong MC, Goggins WB, Wang HH, et al. Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries. Eur Urol. 2016;70:862–874.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.
   PubMed Web of Science ®Google Scholar
• Galper SL, Chen MH, Catalona WJ, et al. Evidence to support a continued stage migration and decrease in prostate cancer specific mortality. J Urol. 2006;175:907–912.
   PubMed Web of Science ®Google Scholar
• Shao YH, Demissie K, Shih W, et al. Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst. 2009;101:1280–1283.
   PubMed Web of Science ®Google Scholar
• Reese AC, Wessel SR, Fisher SG, et al. Evidence of prostate cancer “reverse stage migration” toward more advanced disease at diagnosis: data from the Pennsylvania Cancer Registry. Urol Oncol. 2016;34(335):e21–8.
   Google Scholar
• Budaus L, Spethmann J, Isbarn H, et al. Inverse stage migration in patients undergoing radical prostatectomy: results of 8916 European patients treated within the last decade. BJU Int. 2011;108:1256–1261.
   PubMed Web of Science ®Google Scholar
• Sammon JD, Abdollah F, Choueiri TK, et al. Prostate-specific antigen screening after 2012 US preventive services task force recommendations. JAMA. 2015;314:2077–2079.
   PubMed Web of Science ®Google Scholar
• Zeliadt SB, Hoffman RM, Etzioni R, et al. Influence of publication of US and European prostate cancer screening trials on PSA testing practices. J Natl Cancer Inst. 2011;103:520–523.
   PubMedGoogle Scholar
• Force USPST. Screening for prostate cancer: U.S. preventive services task force recommendation statement. Ann Intern Med. 2008;149:185–191.
   PubMed Web of Science ®Google Scholar
• Andriole GL, Crawford ED, Grubb RL III, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310–1319.
   PubMed Web of Science ®Google Scholar
• Andriole GL, Crawford ED, Grubb RL III, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104:125–132.
   PubMed Web of Science ®Google Scholar
• Pinsky PF, Prorok PC, Yu K, et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer. 2017;123:592–599.
   PubMed Web of Science ®Google Scholar
• Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320–1328.
   PubMed Web of Science ®Google Scholar
• Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384:2027–2035.
   PubMed Web of Science ®Google Scholar
• Tewari A, Sooriakumaran P, Bloch DA, et al. Positive surgical margin and perioperative complication rates of primary surgical treatments for prostate cancer: a systematic review and meta-analysis comparing retropubic, laparoscopic, and robotic prostatectomy. Eur Urol. 2012;62:1–15.
   PubMed Web of Science ®Google Scholar
• Cooperberg MR, Carroll PR. Trends in management for patients with localized prostate cancer, 1990–2013. JAMA. 2015;314:80–82.
   PubMed Web of Science ®Google Scholar
• Surcel CI, Sooriakumaran P, Briganti A, et al. Preferences in the management of high-risk prostate cancer among urologists in Europe: results of a web-based survey. BJU Int. 2015;115:571–579.
   PubMed Web of Science ®Google Scholar
• Gray PJ, Lin CC, Cooperberg MR, et al. Temporal trends and the impact of race, insurance, and socioeconomic status in the management of localized prostate cancer. Eur Urol. 2017;71:729–737.
   PubMed Web of Science ®Google Scholar
• Ward JF, Slezak JM, Blute ML, et al. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int. 2005;95:751–756.
   PubMed Web of Science ®Google Scholar
• Mitchell CR, Boorjian SA, Umbreit EC, et al. 20-Year survival after radical prostatectomy as initial treatment for cT3 prostate cancer. BJU Int. 2012;110:1709–1713.
   PubMed Web of Science ®Google Scholar
• Loeb S, Schaeffer EM, Trock BJ, et al. What are the outcomes of radical prostatectomy for high-risk prostate cancer? Urology. 2010;76:710–714.
   PubMed Web of Science ®Google Scholar
• Inman BA, Davies JD, Rangel LJ, et al. Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level > or =50 ng/mL. Cancer. 2008;113:1544–1551.
   PubMed Web of Science ®Google Scholar
• Yossepowitch O, Eggener SE, Serio AM, et al. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol. 2008;53:950–959.
   PubMed Web of Science ®Google Scholar
• Dell’Oglio P, Karnes RJ, Joniau S, et al. Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer. Urol Oncol. 2016;34(234):e13–9.
   PubMed Web of Science ®Google Scholar
• Gandaglia G, Sammon JD, Chang SL, et al. Comparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era. J Clin Oncol. 2014;32:1419–1426.
   PubMed Web of Science ®Google Scholar
• Briganti A, Bianchi M, Sun M, et al. Impact of the introduction of a robotic training programme on prostate cancer stage migration at a single tertiary referral centre. BJU Int. 2013;111:1222–1230.
   PubMed Web of Science ®Google Scholar
• Trinh QD, Sammon J, Sun M, et al. Perioperative outcomes of robot-assisted radical prostatectomy compared with open radical prostatectomy: results from the nationwide inpatient sample. Eur Urol. 2012;61:679–685.
   PubMed Web of Science ®Google Scholar
• Tsui C, Klein R, Garabrant M. Minimally invasive surgery: national trends in adoption and future directions for hospital strategy. Surg Endosc. 2013;27:2253–2257.
   PubMed Web of Science ®Google Scholar
• Lavery HJ, Nabizada-Pace F, Carlucci JR, et al. Nerve-sparing robotic prostatectomy in preoperatively high-risk patients is safe and efficacious. Urol Oncol. 2012;30:26–32.
   PubMed Web of Science ®Google Scholar
• Connolly SS, Cathcart PJ, Gilmore P, et al. Robotic radical prostatectomy as the initial step in multimodal therapy for men with high-risk localised prostate cancer: initial experience of 160 men. BJU Int. 2012;109:752–759.
   PubMed Web of Science ®Google Scholar
• Jung JH, Seo JW, Lim MS, et al. Extended pelvic lymph node dissection including internal iliac packet should be performed during robot-assisted laparoscopic radical prostatectomy for high-risk prostate cancer. J Laparoendosc Adv Surgl Tech Part. 2012;22:785–790.
   PubMed Web of Science ®Google Scholar
• Zugor V, Witt JH, Heidenreich A, et al. Surgical and oncological outcomes in patients with preoperative PSA >20 ng/ml undergoing robot-assisted radical prostatectomy. Anticancer Res. 2012;32:2091–2095.
   PubMed Web of Science ®Google Scholar
• Yuh BE, Ruel NH, Mejia R, et al. Robotic extended pelvic lymphadenectomy for intermediate- and high-risk prostate cancer. Eur Urol. 2012;61:1004–1010.
   PubMed Web of Science ®Google Scholar
• Ou YC, Yang CK, Wang J, et al. The trifecta outcome in 300 consecutive cases of robotic-assisted laparoscopic radical prostatectomy according to D’Amico risk criteria. Eur J Surg Oncol. 2013;39:107–113.
   PubMed Web of Science ®Google Scholar
• Sagalovich D, Calaway A, Srivastava A, et al. Assessment of required nodal yield in a high risk cohort undergoing extended pelvic lymphadenectomy in robotic-assisted radical prostatectomy and its impact on functional outcomes. BJU Int. 2013;111:85–94.
   PubMed Web of Science ®Google Scholar
• Punnen S, Meng MV, Cooperberg MR, et al. How does robot-assisted radical prostatectomy (RARP) compare with open surgery in men with high-risk prostate cancer? BJU Int. 2013;112:E314–20.
   PubMed Web of Science ®Google Scholar
• Rogers CG, Sammon JD, Sukumar S, et al. Robot assisted radical prostatectomy for elderly patients with high risk prostate cancer. Urol Oncol. 2013;31:193–197.
   PubMed Web of Science ®Google Scholar
• Silberstein JL, Su D, Glickman L, et al. A case-mix-adjusted comparison of early oncological outcomes of open and robotic prostatectomy performed by experienced high volume surgeons. BJU Int. 2013;111:206–212.
   PubMed Web of Science ®Google Scholar
• Brennhovd B, Axcrona K, Fossa SD, et al. Robot-assisted radical prostatectomy of clinical high-risk patients with prostate cancer: a controlled study of operative and short-term postoperative events. Scand J Urol. 2013;47:449–455.
   PubMed Web of Science ®Google Scholar
• Busch J, Magheli A, Leva N, et al. Matched comparison of outcomes following open and minimally invasive radical prostatectomy for high-risk patients. World J Urol. 2014;32:1411–1416.
   PubMed Web of Science ®Google Scholar
• Pierorazio PM, Mullins JK, Eifler JB, et al. Contemporaneous comparison of open vs minimally-invasive radical prostatectomy for high-risk prostate cancer. BJU Int. 2013;112:751–757.
   PubMed Web of Science ®Google Scholar
• Harty NJ, Kozinn SI, Canes D, et al. Comparison of positive surgical margin rates in high risk prostate cancer: open versus minimally invasive radical prostatectomy. Int Braz J Urol. 2013;39:639-46; discussion 47-8.
   PubMed Web of Science ®Google Scholar
• Suardi N, Larcher A, Haese A, et al. Indication for and extension of pelvic lymph node dissection during robot-assisted radical prostatectomy: an analysis of five European institutions. Eur Urol. 2014;66:635–643.
   PubMed Web of Science ®Google Scholar
• Diaz M, Peabody JO, Kapoor V, et al. Oncologic outcomes at 10 years following robotic radical prostatectomy. Eur Urol. 2015;67:1168–1176.
   PubMed Web of Science ®Google Scholar
• Wang JG, Huang J, Chin AI. RARP in high-risk prostate cancer: use of multi-parametric MRI and nerve sparing techniques. Asian J Androl. 2014;16:715–719.
   PubMed Web of Science ®Google Scholar
• Gandaglia G, Abdollah F, Hu J, et al. Is robot-assisted radical prostatectomy safe in men with high-risk prostate cancer? Assessment of perioperative outcomes, positive surgical margins, and use of additional cancer treatments. J Endourol. 2014;28:784–791.
   PubMed Web of Science ®Google Scholar
• Koo KC, Jung DC, Lee SH, et al. Feasibility of robot-assisted radical prostatectomy for very-high risk prostate cancer: surgical and oncological outcomes in men aged >/=70 years. Prostate International. 2014;2:127–132.
   PubMedGoogle Scholar
• Abdollah F, Dalela D, Sood A, et al. Intermediate-term cancer control outcomes in prostate cancer patients treated with robotic-assisted laparoscopic radical prostatectomy: a multi-institutional analysis. World J Urol. 2016;34:1357–1366.
   PubMed Web of Science ®Google Scholar
• Abdollah F, Sood A, Sammon JD, et al. Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients. Eur Urol. 2015;68:497–505.
   PubMed Web of Science ®Google Scholar
• Hu JC, Gandaglia G, Karakiewicz PI, et al. Comparative effectiveness of robot-assisted versus open radical prostatectomy cancer control. Eur Urol. 2014;66:666–672.
   PubMed Web of Science ®Google Scholar
• Suardi N, Dell’Oglio P, Gallina A, et al. Evaluation of positive surgical margins in patients undergoing robot-assisted and open radical prostatectomy according to preoperative risk groups. Urol Oncol. 2016;34(57):e1–7.
   PubMed Web of Science ®Google Scholar
• Lee D, Choi SK, Park J, et al. Comparative analysis of oncologic outcomes for open vs. robot-assisted radical prostatectomy in high-risk prostate cancer. Korean J Urol. 2015;56:572–579.
   PubMedGoogle Scholar
• Kumar A, Samavedi S, Bates AS, et al. Safety of selective nerve sparing in high risk prostate cancer during robot-assisted radical prostatectomy. J Robot Surg. 2017;11:129–138.
   PubMed Web of Science ®Google Scholar
• Srougi V, Tourinho-Barbosa RR, Nunes-Silva I, et al. The role of robot-assisted radical prostatectomy in high-risk prostate cancer. J Endourol. 2017;31:229–237.
   PubMed Web of Science ®Google Scholar
• Abdollah F, Dalela D, Sood A, et al. Functional outcomes of clinically high-risk prostate cancer patients treated with robot-assisted radical prostatectomy: a multi-institutional analysis. Prostate Cancer Prostatic Dis. 2017.
   PubMedGoogle Scholar
• Lee EK, Baack J, Duchene DA. Survey of practicing urologists: robotic versus open radical prostatectomy. Can J Urol. 2010;17:5094–5098. DOI: 10.1038/pcan.2017.26.
   PubMed Web of Science ®Google Scholar
• Morris WJ, Tyldesley S, Rodda S, et al. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2017;98:275–285.
   PubMed Web of Science ®Google Scholar
• Hoskin PJ, Rojas AM, Bownes PJ, et al. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol. 2012;103:217–222.
   PubMed Web of Science ®Google Scholar
• Guidelines on prostate cancer. European Association of Urology. 2017 cited 2017 May. Available from: http://uroweb.org/guideline/prostate-cancer/
   Google Scholar
• Bolla M, van Poppel H. Management of prostate cancer. A multidisciplinary approach. 2nd ed. Switzerland: Springer International Publishing; 2017. Chapter 17, High-Intensity Focused Ultrasound (HIFU) for Prostate Cancer; p. 251-272. Chapter 18, Prostate Cryotherapy; p. 273–285.
   Google Scholar
• Polascik TJ. Imaging and focal therapy of early prostate cancer. 2nd ed. Switzerland: Springer International Publishing AG; 2017. Chapter 10, Patient Selection for Focal Therapy of Prostate Cancer; p. 129-138. Chapter 22, Focal Cryotherapy; p. 283-292. Chapter 24, High-Intensity Focused Ultrasound; p. 309–324.
   Google Scholar
• Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655–1659.
   PubMed Web of Science ®Google Scholar
• Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358:966–970.
   PubMed Web of Science ®Google Scholar
• Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–1259.
   PubMed Web of Science ®Google Scholar
• Glehen O, Mohamed F, Gilly FN. Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol. 2004;5:219–228.
   PubMed Web of Science ®Google Scholar
• Thompson IM, Tangen C, Basler J, et al. Impact of previous local treatment for prostate cancer on subsequent metastatic disease. J Urol. 2002;168:1008–1012.
   PubMed Web of Science ®Google Scholar
• Shao YH, Kim S, Moore DF, et al. Cancer-specific survival after metastasis following primary radical prostatectomy compared with radiation therapy in prostate cancer patients: results of a population-based, propensity score-matched analysis. Eur Urol. 2014;65:693–700.
   PubMed Web of Science ®Google Scholar
• Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol. 2014;65:1058–1066.
   PubMed Web of Science ®Google Scholar
• Gratzke C, Engel J, Stief CG. Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry. Eur Urol. 2014;66:602–603.
   PubMed Web of Science ®Google Scholar
• Fossati N, Trinh QD, Sammon J, et al. Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study. Eur Urol. 2015;67:3–6.
   PubMed Web of Science ®Google Scholar
• Antwi S, Everson TM. Prognostic impact of definitive local therapy of the primary tumor in men with metastatic prostate cancer at diagnosis: a population-based, propensity score analysis. Cancer Epidemiol. 2014;38:435–441.
   PubMed Web of Science ®Google Scholar
• Satkunasivam R, Kim AE, Desai M, et al. Radical prostatectomy or external beam radiation therapy vs. no local therapy for survival benefit in metastatic prostate cancer: a SEER-medicare analysis. J Urol. 2015;194:378–385.
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Pfister D, Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. J Urol. 2015;193:832–838.
   PubMed Web of Science ®Google Scholar
• Sooriakumaran P, Karnes J, Stief C, et al. A multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation. Eur Urol. 2016;69:788–794.
   PubMed Web of Science ®Google Scholar
• Loppenberg B, Dalela D, Karabon P, et al. The impact of local treatment on overall survival in patients with metastatic prostate cancer on diagnosis: a national cancer data base analysis. Eur Urol. 2017;72:14–19.
   PubMed Web of Science ®Google Scholar
• Rusthoven CG, Jones BL, Flaig TW, et al. Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer. J Clin Oncol. 2016;34:2835–2842.
   PubMed Web of Science ®Google Scholar
• Gandaglia G, Fossati N, Stabile A, et al. Radical prostatectomy in men with oligometastatic prostate cancer: results of a single-institution series with long-term follow-up. Eur Urol. 2017;72:289–292.
   PubMed Web of Science ®Google Scholar
• Moschini M, Morlacco A, Kwon E, et al. Treatment of M1a/M1b prostate cancer with or without radical prostatectomy at diagnosis. Prostate Cancer Prostatic Dis. 2017;20:117–121.
   PubMed Web of Science ®Google Scholar
• Parikh RR, Byun J, Goyal S, et al. Local therapy improves overall survival in patients with newly diagnosed metastatic prostate cancer. Prostate. 2017;77:559–572.
   PubMed Web of Science ®Google Scholar
• Leyh-Bannurah SR, Gazdovich S, Budaus L, et al. Local therapy improves survival in metastatic prostate cancer. Eur Urol. 2017;72:118–124.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Clinical practice guidelines in oncology (NCCN Guidelines®). Prostate cancer. 2017 cited 2017 May. Available from: https://www.nccn.org/professionals/physician_gls/f_guidelines.asp
   Google Scholar
• Yossepowitch O, Eastham JA. Radical prostatectomy for high-risk prostate cancer. World J Urol. 2008;26:219–224.
   PubMed Web of Science ®Google Scholar
• Spahn M, Joniau S, Gontero P, et al. Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. Eur Urol. 2010;58:1-7; discussion 10-1.
   Web of Science ®Google Scholar
• Kaplan RN, Rafii S, Lyden D. Preparing the “soil”: the premetastatic niche. Cancer Res. 2006;66:11089–11093.
   PubMed Web of Science ®Google Scholar
• Gandaglia G, Trinh QD, Hu JC, et al. The impact of robot-assisted radical prostatectomy on the use and extent of pelvic lymph node dissection in the “post-dissemination” period. Eur J Surg Oncol. 2014;40:1080–1086.
   PubMed Web of Science ®Google Scholar
• Schiffmann J, Haese A, Leyh-Bannurah SR, et al. Adherence of the indication to European Association of Urology guideline recommended pelvic lymph node dissection at a high-volume center: differences between open and robot-assisted radical prostatectomy. Eur J Surg Oncol. 2015;41:1547–1553.
   PubMed Web of Science ®Google Scholar
• Yaxley JW, Coughlin GD, Chambers SK, et al. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study. Lancet. 2016;388:1057–1066.
   PubMed Web of Science ®Google Scholar
• Briganti A, Larcher A, Abdollah F, et al. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol. 2012;61:480–487.
   PubMed Web of Science ®Google Scholar
• Briganti A, Capitanio U, Chun FK, et al. Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer. Eur Urol. 2008;54:794–802.
   PubMed Web of Science ®Google Scholar
• Silberstein JL, Vickers AJ, Power NE, et al. Pelvic lymph node dissection for patients with elevated risk of lymph node invasion during radical prostatectomy: comparison of open, laparoscopic and robot-assisted procedures. J Endourol. 2012;26:748–753.
   PubMed Web of Science ®Google Scholar
• Wit EM, Acar C, Grivas N, et al. Sentinel node procedure in prostate cancer: a systematic review to assess diagnostic accuracy. Eur Urol. 2017;71:596–605.
   PubMed Web of Science ®Google Scholar
• Maurer T, Weirich G, Schottelius M, et al. Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer. Eur Urol. 2015;68:530–534.
   PubMed Web of Science ®Google Scholar
• Dell’Oglio P, Stabile A, Zaffuto E, et al. Surgical expertise is the major determinant of decreased complication rates in contemporary patients treated with robot-assisted radical prostatectomy. Eur Urol Suppl. 2017;16:e1888–e9.
   Google Scholar
• Joniau S, Briganti A, Gontero P, et al. Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study. Eur Urol. 2015;67:157–164.
   PubMed Web of Science ®Google Scholar
• Pompe RS, Karakiewicz PI, Tian Z, et al. Oncological and functional outcomes after radical prostatectomy for high or very high-risk prostate cancer - European validation of the current NCCN guideline. J Urol. 2017. DOI:10.1016/j.juro.2017.02.070.
   PubMed Web of Science ®Google Scholar
• Ficarra V, Novara G, Rosen RC, et al. Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol. 2012;62:405–417.
   PubMed Web of Science ®Google Scholar
• Ficarra V, Novara G, Ahlering TE, et al. Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol. 2012;62:418–430.
   PubMed Web of Science ®Google Scholar
• Ost P, Decaestecker K, Lambert B, et al. Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer. Prostate. 2014;74:297–305.
   PubMed Web of Science ®Google Scholar
• Gandaglia G, Karakiewicz PI, Briganti A, et al. Impact of the site of metastases on survival in patients with metastatic prostate cancer. Eur Urol. 2015;68:325–334.
   PubMed Web of Science ®Google Scholar
• Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8–10.
   PubMed Web of Science ®Google Scholar
• Paget S. The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev. 1989;8:98–101.
   PubMed Web of Science ®Google Scholar
• Gandaglia G, Fossati N, Dell’Oglio P, et al. Rationale for local treatment in the management of metastatic prostate cancer. Curr Opin Support Palliat Care. 2016;10:266–272.
   PubMed Web of Science ®Google Scholar
• Steinberg GD, Epstein JI, Piantadosi S, et al. Management of stage D1 adenocarcinoma of the prostate: the Johns Hopkins experience 1974 to 1987. J Urol. 1990;144:1425–1432.
   PubMed Web of Science ®Google Scholar
• Won AC, Gurney H, Marx G, et al. Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer. BJU Int. 2013;112:E250–5.
   PubMed Web of Science ®Google Scholar
• Berg KD, Thomsen FB, Mikkelsen MK, et al. Improved survival for patients with de novo metastatic prostate cancer in the last 20 years. Eur J Cancer. 2017;72:20–27.
   PubMed Web of Science ®Google Scholar
• Kadmon D, Heston WD, Fair WR. Treatment of a metastatic prostate derived tumor with surgery and chemotherapy. J Urol. 1982;127:1238–1242.
   PubMed Web of Science ®Google Scholar
• Jarosek SL, Virnig BA, Chu H, et al. Propensity-weighted long-term risk of urinary adverse events after prostate cancer surgery, radiation, or both. Eur Urol. 2015;67:273–280.
   PubMed Web of Science ®Google Scholar